Announcement no. 16/2026
13 March 2026
Reference is made to announcement no. 15/2026 published on 10 March 2026 (Embla Medical: Results of the Annual General Meeting 2026).
Reykjavik, Iceland/Copenhagen, Denmark, March 13, 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the capital reduction of ISK 2,441,257 nominal value was registered with the Icelandic Register of Enterprises today. 2,441,257 of the Company's own shares with a nominal value of ISK 1 each were cancelled.
The share capital of Embla Medical is now ISK 428,000,000 nominal value divided into the same number of shares with a nominal value of ISK each. The Company currently holds 642,442 own shares.
Further information
Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134
Embla Medical press releases by e-mail
If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors
About Embla Medical
Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations®. Embla Medical is home to several leading brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women's Empowerment Principles and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com